Cargando…
Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide, because recurrence often occurs in most HCC patients undergoing hepatectomy. It is necessary to identify patients with high risk for recurrence and adopt effective therapies. An obstacle to monitor patients at hig...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514049/ https://www.ncbi.nlm.nih.gov/pubmed/28717245 http://dx.doi.org/10.1038/s41598-017-04811-5 |
_version_ | 1783250766895513600 |
---|---|
author | Li, Binghua Feng, Wendu Luo, Ouyang Xu, Tiancheng Cao, Yajuan Wu, Hongyan Yu, Decai Ding, Yitao |
author_facet | Li, Binghua Feng, Wendu Luo, Ouyang Xu, Tiancheng Cao, Yajuan Wu, Hongyan Yu, Decai Ding, Yitao |
author_sort | Li, Binghua |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide, because recurrence often occurs in most HCC patients undergoing hepatectomy. It is necessary to identify patients with high risk for recurrence and adopt effective therapies. An obstacle to monitor patients at high risk for poor prognosis has been the lack of useful predictive biomarkers. Fortunately, recent progress in system biology allows to screen the biomarkers for HCC prognosis in a high-throughput manner. In this study, we performed systematic Kaplan-Meier survival analysis of the whole mRNA transcriptomics based on the Cancer Genome Atlas project (TCGA) and developed a three-gene prognostic signature composing of three genes UPB1, SOCS2 and RTN3. The model was validated in two independent microarray data sets retrieved from Gene Expression Omnibus (GEO) and the expression pattern of these three predictive genes in HCC was confirmed by western blot and immunohistochemistry with our HCC samples. In conclusion, our results showed that this three-gene signature has prognostic value for HCC patients. |
format | Online Article Text |
id | pubmed-5514049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-55140492017-07-19 Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma Li, Binghua Feng, Wendu Luo, Ouyang Xu, Tiancheng Cao, Yajuan Wu, Hongyan Yu, Decai Ding, Yitao Sci Rep Article Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide, because recurrence often occurs in most HCC patients undergoing hepatectomy. It is necessary to identify patients with high risk for recurrence and adopt effective therapies. An obstacle to monitor patients at high risk for poor prognosis has been the lack of useful predictive biomarkers. Fortunately, recent progress in system biology allows to screen the biomarkers for HCC prognosis in a high-throughput manner. In this study, we performed systematic Kaplan-Meier survival analysis of the whole mRNA transcriptomics based on the Cancer Genome Atlas project (TCGA) and developed a three-gene prognostic signature composing of three genes UPB1, SOCS2 and RTN3. The model was validated in two independent microarray data sets retrieved from Gene Expression Omnibus (GEO) and the expression pattern of these three predictive genes in HCC was confirmed by western blot and immunohistochemistry with our HCC samples. In conclusion, our results showed that this three-gene signature has prognostic value for HCC patients. Nature Publishing Group UK 2017-07-17 /pmc/articles/PMC5514049/ /pubmed/28717245 http://dx.doi.org/10.1038/s41598-017-04811-5 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Li, Binghua Feng, Wendu Luo, Ouyang Xu, Tiancheng Cao, Yajuan Wu, Hongyan Yu, Decai Ding, Yitao Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma |
title | Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma |
title_full | Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma |
title_fullStr | Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma |
title_full_unstemmed | Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma |
title_short | Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma |
title_sort | development and validation of a three-gene prognostic signature for patients with hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514049/ https://www.ncbi.nlm.nih.gov/pubmed/28717245 http://dx.doi.org/10.1038/s41598-017-04811-5 |
work_keys_str_mv | AT libinghua developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma AT fengwendu developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma AT luoouyang developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma AT xutiancheng developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma AT caoyajuan developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma AT wuhongyan developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma AT yudecai developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma AT dingyitao developmentandvalidationofathreegeneprognosticsignatureforpatientswithhepatocellularcarcinoma |